PHARMACIST INCENTIVES AND COMPENSATION FOR SERVICES
Executive Summary
PHARMACIST INCENTIVES AND COMPENSATION FOR SERVICES should be part of the drug reimbursement system under Medicaid, the American Society of Hospital Pharmacists (ASHP) maintained in a March 13 letter to HHS Secretary Bowen. "ASHP strongly urges the department to meet the challenge of developing a new, equitable and comprehensive drug reimbursement program which combines incentives for pharmacists to provide the most cost-effective pharmaceutical products with commensurate compensation for services," association Exec VP Joseph Oddis wrote. "To date, efforts to address the need for a new system of pharmacy payment have been unsuccessful," Oddis said. "Efforts to adjust the existing -- and in our view only marginally effective -- MAC program were inartful and only served to perpetuate a system in which product-related costs inappropriately subsidize the cost of professional services. Current proposals simply play with numbers without addressing the issue foursquare," he added. ASHP contended that to establish a new system that is free from "past inequities imposed upon both the government and the profession," the department should set five criteria for its Rx drug reimbursement program: The system should allow for budget limitations, It should "minimize administrative costs to pharmacists and reduce government overhead costs", It should "use marketplace incentives to encourage cost control", Reimbursement should include both product costs and "an incentive to use lower-cost products where possible" and, It should "include payment for professional services."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth